May 11 (Reuters) - Hims & Hers Health raised its 2026 revenue forecast on Monday, betting on increased sales for its ...

Up 1 hour ago Live That wraps up our initial coverage of Hims and Hers Health’s Q1 results. Thank you for stopping by! Check ...

The telehealth platform also warned it could face further profit pressures ahead, citing heavier investments in areas such as ...

Quarterly filings reveal markedly different revenue trajectories and margin profiles for these two healthcare platforms. What ...

Hims & Hers Health reported first-quarter 2026 results with revenue of US$608.1 million, up from US$586.01 million a year earlier, but moved from net income of US$49.49 million to a net loss of US$92.

Hims & Hers Health, Inc. HIMS shares fell in Tuesday premarket trading after the telehealth company reported first-quarter results that missed Wall Street expectations on both earnings and revenue.

Hims & Hers Health, Inc. HIMS reported quarterly adjusted loss per share of 18 cents in first-quarter 2026, against the ...

Hims & Hers shares fell 15% after first-quarter earnings miss. Company posted a surprise loss tied to GLP-1 restructuring ...

The pace of first quarter earnings reports eases this week as economic data takes center stage, but investors will still be ...

Hims & Hers Health, Inc. remains a Buy, with a solid bottom forming despite recent margin and revenue challenges. Read more ...

Hims & Hers Health raised its 2026 revenue forecast on ​Monday, betting on ‌increased sales for its personalized healthcare ...

Feb 7 (Reuters) - Online telehealth company Hims & Hers ‌on Saturday reversed course on its launch of a $49 ‌compounded version of Novo Nordisk's Wegovy weight-loss pill after the U.S. Food and Drug ...